Sangamo Therapeutics' (SGMO) cash on its balance sheet remains "an overhang" following Pfizer's (PFE) decision to terminate a hemophilia A gene therapy collaboration with the company, Truist Securities said in a Monday note.
The partnership and license agreement between the two companies are anticipated to close in Q1 next year and while the company's management had hinted that a biologics license application would "trigger a meaningful payment to help cash runway," it seems difficult now without a significant cash infusion in Q1 2025, analysts led by Nicole Germino wrote.
Truist Securities maintained a buy rating on the company's stock with a $7 price target.
SGMO shares were down 55% in recent premarket activity.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。